Home » Newsletters » BioWorld Science

BioWorld Science

May 2, 2022

View Archived Issues

BBT-207, a fourth-generation EGFR TKI with activity against most common mutants

Bristol Myers Squibb describes new FPR1/2 agonists

New KCNA3 channel blockers identified at DE Shaw Research

Vertex Pharmaceuticals discovers CFTR modulators

Curome Biosciences presents new quinone derivatives

New mucolipin-1 activators identified at Lysoway Therapeutics

Innate immune memory underlies inflammatory comorbidities: study

CF-370 shows synergy with amikacin in drug-resistant P. aeruginosa acute pneumonia model

BioNova Pharmaceuticals menin inhibitor BNM-1192 shows promise for MLL rearranged leukemias

Bridge Biotherapeutics and Cyrus Therapeutics generate next-generation EGFR degraders

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 12, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for June 9, 2026
Pre-disease plasma signature may help redefine lung cancer risk
BioWorld
Researchers have identified a 14-protein blood signature that can predict lung cancer risk as much as five years before diagnosis, and the findings could help...
Europe’s Alzecure, Orionis in $1B+ deals with Lilly, Novartis
BioWorld
Two companies with European ties signed billion-dollar deals with large pharma firms in the last two days to discover and develop molecular glue drugs, as well as...
Ethyreal launches to treat the underlying cause of Graves’, TED
BioWorld
Ethyreal Bio Inc. has come out of stealth mode in order to disclose preclinical data for ETHY-001, its monoclonal antibody targeting thyroid stimulating hormone...